908 related articles for article (PubMed ID: 30395395)
1. Bullous autoimmune dermatoses.
Hofmann SC; Juratli HA; Eming R
J Dtsch Dermatol Ges; 2018 Nov; 16(11):1339-1358. PubMed ID: 30395395
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of autoimmune bullous diseases in Middle Franconia.
Sollfrank L; Schönfelder V; Sticherling M
Front Immunol; 2023; 14():1256617. PubMed ID: 37881435
[TBL] [Abstract][Full Text] [Related]
3. [Autoimmune bullous skin disorders].
Hertl M; Niedermeier A; Borradori L
Ther Umsch; 2010 Sep; 67(9):465-82. PubMed ID: 20806175
[TBL] [Abstract][Full Text] [Related]
4. Nutrition and bullous diseases.
Stoj V; Lu J
Clin Dermatol; 2022; 40(2):156-165. PubMed ID: 34808244
[TBL] [Abstract][Full Text] [Related]
5. Current treatment of autoimmune blistering diseases.
Kasperkiewicz M; Schmidt E
Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595
[TBL] [Abstract][Full Text] [Related]
6. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.
Santi CG; Gripp AC; Roselino AM; Mello DS; Gordilho JO; Marsillac PF; Porro AM
An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):33-47. PubMed ID: 31166405
[TBL] [Abstract][Full Text] [Related]
7. [Bullous autoimmune dermatoses of the mucous membranes].
Didona D; Hinterseher J; Eming R
Dermatologie (Heidelb); 2022 Sep; 73(9):692-700. PubMed ID: 36006424
[TBL] [Abstract][Full Text] [Related]
8. Blistering diseases in the mature patient.
Lakoš Jukić I; Jerković Gulin S; Marinović B
Clin Dermatol; 2018; 36(2):231-238. PubMed ID: 29566927
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
10. [Epidermolysis bullosa acquisita].
Hofmann SC; Weidinger A
Hautarzt; 2019 Apr; 70(4):265-270. PubMed ID: 30887080
[TBL] [Abstract][Full Text] [Related]
11. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy.
Kianfar N; Dasdar S; Daneshpazhooh M; Aryanian Z; Goodarzi A
Exp Dermatol; 2023 Jul; 32(7):934-944. PubMed ID: 37150538
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune bullous skin diseases. Part 1: Clinical manifestations.
Kneisel A; Hertl M
J Dtsch Dermatol Ges; 2011 Oct; 9(10):844-56; quiz 857. PubMed ID: 21955378
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic approaches and targets for treatment of autoimmune bullous diseases.
Bardazzi F; Loi C; Chessa Marco A; Di Altobrando A; Filippi F; Lacava R; Viviani F; Balestri R; Leuzzi M; Sacchelli L
Dermatol Ther; 2021 Sep; 34(5):e15032. PubMed ID: 34145701
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.
Kim M; Borradori L; Murrell DF
Drugs Aging; 2016 Oct; 33(10):711-723. PubMed ID: 27738963
[TBL] [Abstract][Full Text] [Related]
15. [Bullous autoimmune diseases of the oral mucosa].
Vaillant L
Rev Stomatol Chir Maxillofac; 1999 Oct; 100(5):230-9. PubMed ID: 10604215
[TBL] [Abstract][Full Text] [Related]
16. New immunomodulating drugs in autoimmune blistering diseases.
Korman NJ
Dermatol Clin; 2001 Oct; 19(4):637-48, viii. PubMed ID: 11705351
[TBL] [Abstract][Full Text] [Related]
17. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune bullous dermatoses.
Holtsche MM; Boch K; Schmidt E
J Dtsch Dermatol Ges; 2023 Apr; 21(4):405-412. PubMed ID: 37070500
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease.
Hashimoto T; Ishii N; Ohata C; Furumura M
J Pathol; 2012 Sep; 228(1):1-7. PubMed ID: 22692770
[TBL] [Abstract][Full Text] [Related]
20. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab.
Wallet-Faber N; Franck N; Batteux F; Mateus C; Gilbert D; Carlotti A; Avril MF; Dupin N
Dermatology; 2007; 215(3):252-5. PubMed ID: 17823525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
